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Streptococcus pyogenes throat infection is a clinically relevant trigger of both guttate 
and chronic plaque psoriasis, and it provides an ideal context in which to study the 
pathogenesis of these diseases using an antigen-dependent approach. Circulating 
cutaneous lymphocyte-associated antigen (CLA) positive (+) memory T  cells are a 
subset of peripheral lymphocytes whose phenotype and function are related to immu-
nological mechanisms in the skin. These cells are considered peripheral biomarkers of 
T-cell-mediated skin diseases. The coculture of autologous epidermal cells with CLA+ 
T  cells from psoriasis patients activated by S. pyogenes allows the reproduction of 
the ex vivo initial molecular events that occur during psoriatic lesion formation. With 
cooperation of autologous epidermal cells, S. pyogenes selectively activates CLA+ 
T  cells both in guttate and plaque psoriasis, inducing key mediators, including an 
IL-17 response. Here, we explore potential new mechanisms of psoriasis development 
including the influence of HLA-Cw6 on S. pyogenes CLA+ T cell activation in guttate 
psoriasis, the relevance of IL-9 on microbe induced IL-17 response in guttate and 
plaque psoriasis, and novel effector functions of Candida albicans. This review will 
summarize recent knowledge of psoriatic mechanisms elicited by microbes that have 
been studied through an innovative translational perspective based on CLA+ T cell-me-
diated cutaneous immune response.
Keywords: psoriasis, cutaneous lymphocyte-associated antigen, homing, Candida albicans, Streptococcus 
pyogenes
inTRODUCTiOn
Molecular studies of psoriasis lesions and patients have allowed translational research to generate 
potent and novel therapies (1). However, our understanding of the influence of environmental 
factors on the psoriatic cutaneous immune response is still limited (1). Several microorganisms, 
including bacteria, fungi, and viruses, have been postulated to be potential triggers and/or exac-
erbating factors of psoriasis (2). Bacterial genome DNA sequencing in psoriasis is an area of great 
interest, some microorganisms have been identified but their functional relevance for psoriasis is 
still to be determined. Psoriasis can be classified as early or late onset (3). The former is associated 
with the HLA-Cw6 allele, streptococcal throat infection, and a higher tendency to be generalized 
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(4, 5). Interestingly, patients with this type often present a more 
intense inflammatory lymphocytic infiltrate and are more likely 
to receive biological therapy (6). All these observations suggest 
that the presentation of psoriasis is associated with the present 
bacterial infection. Streptococcus pyogenes throat infection is a 
well-characterized infectious trigger of gutatte psoriasis (GP) 
and chronic plaque psoriasis (CPP). More than 60  years ago, 
it was reported that two-third of GP patients present an acute 
sore throat 12  weeks before the skin eruption (7). Similarly, 
CPP can also be triggered by S. pyogenes throat infections 
(8), and interestingly, CPP patients have a higher incidence 
of recurrent sore throats compared with controls (9, 10). The 
presence of S. pyogenes has been detected in the blood of both 
GP and CPP patients (11). In addition, tonsillectomy can be a 
useful therapeutic intervention in CPP patients with a history 
of streptococcal-associated exacerbations (12). It has been 
proposed that psoriasis tonsillar CLA+ T cells (13) activated by 
streptococcal antigens migrate to the skin where they react to 
antigens that share sequence homology with the streptococcal 
proteins (14). However, other microbes may also participate 
in psoriasis. Fungal cutaneous infections caused by Candida 
albicans have been associated with exacerbation of the disease 
and a higher frequency of intestinal C. albicans isolation in pso-
riasis patients than controls has been reported (2), although the 
mechanisms involved in C. albicans-induced psoriasis remain 
poorly characterized.
Interestingly, microbes such as C. albicans induce type I inter-
feron response and, type I interferon production by plasmacytoid 
dendritic cells in skin has been stated to be an important trigger 
for psoriasis development (15). However, clinical efficacy block-
ing antibodies against IFN-α have not shown clinical efficacy in 
psoriasis (16), rising questions about the translational relevance 
of this mechanism.
In this review, we cover the current state of the art in psoriasis 
immunopathogenic mechanisms brought out by disease-related 
microorganisms, such as S. pyogenes or C. albicans. We focus on 
cutaneous immune response mediated by CLA+ T cells and how 
these microbes affect T cell activation and production of clinically 
relevant cytokines.
CiRCULATinG CLA+ T CeLLS AnD THe 
STUDY OF THe CUTAneOUS iMMUne 
SYSTeM
The immune responses of T  cells during cutaneous chronic 
inflammation in psoriasis involve a subset of memory T lympho-
cytes that can be distinguished from other memory T cells by 
the surface expression of the cutaneous lymphocyte-associated 
antigen (CLA) antigen. This antigen is a cell surface carbo-
hydrate that allows the identification of memory T cells that 
belong to the cutaneous immune system. CLA is an adhesion 
molecule expressed by 15% of circulating T cells in humans, 
and by most (>90%) skin-infiltrating T  cells, contrary to 
other inflamed organs (17). In addition to several ligands for 
chemokine receptors (CCR10, CCR4, CCR6, and CCR8), CLA 
binds to E-selectin and together with the interaction between 
the very late antigen-4/vascular cell adhesion protein-1 and lym-
phocyte function-associated antigen-1/intercellular adhesion 
molecule-1, forms a code bar system enabling skin lymphoid 
infiltration (18). The relevance of circulating CLA+ T cells in the 
cutaneous immune response lies not only in the skin-seeking 
capacity of these cells but also in their functional relation to the 
immune response that occurs in inflamed cutaneous lesions. 
This feature is derived from the recirculating capacity of these 
cells between skin lesion and blood during cutaneous inflam-
mation (18, 19). The antigen-specific response and phenotype 
of circulating CLA+ T cells has been studied in many human 
skin conditions. CLA+ T cells respond to antigens, allergens, 
or superantigens involved in disease by triggering T  cell-
mediated skin diseases, such as psoriasis, atopic dermatitis, 
and contact dermatitis (18). Furthermore, the phenotype 
and function of these cells are related to the clinical status of 
the patient, thereby explaining why circulating CLA+ T cells 
are considered peripheral cell biomarkers of T cell-mediated 
cutaneous disease in humans (18). Using CLA+ T  cells from 
psoriasis patients and healthy controls, our group explores 
the influence of microbes on cutaneous immune response in 
psoriasis.
CLA+ T CeLL ACTivATiOn BY S. pyogenes 
in PSORiASiS inDUCeS iL-17 AnD iL-9 
ReSPOnSeS
Studying the antigen-specific immune response of CLA+ T cells 
induced by clinically relevant triggers of psoriasis may allow 
the identification of the translational mechanisms involved in 
psoriasis. The stimulation of autologous coculture CLA+ T cells 
and epidermal cells with S. pyogenes leads to an inflammatory 
immune response that shows the hallmarks of psoriasis. By 
contrast, the same stimulation of CLA− cells from the same 
patient or cultures using CLA+/CLA− T  cells from healthy 
controls does not have this effect (20). The CLA+ T cell response 
in this model is related to the clinical response of patients in 
terms of anti-streptolysin O levels, PASI, and duration of flare in 
GP (21), and to anti-streptolysin O in CPP (20). This activation 
is determined by the presence of autologous epidermal cells 
(lesional/non-lesional) and MHC class I and class II presenta-
tion. Supernatants of S. pyogenes-activated cocultures of CLA+ 
T cells and epidermal cells induce epidermal hyperplasia upon 
intradermal injection in mouse skin (20). IL-17A and IL-17F 
production is probably the most relevant effect of S. pyogenes on 
CLA+ T cells in psoriasis. The influence of S. pyogenes through 
the response of these cells and the relevance of IL-17 produc-
tion in GP have been extensively studied (21). In HLA-Cw6+ 
patients whose GP flare is associated with a pharyngitis episode, 
the Th17-associated response is greater than that exerted by 
samples from GP patients not associated with pharyngitis. In 
fact, significantly higher levels of IL-17A, IL-17F, and even IL-6, 
which participates in Th17-differentiation, were found (21). 
Thus, the observed response of psoriasis memory T cells to S. 
pyogenes seems to be restricted to CLA+ T cells, leading to IL-17 
production. This cytokine is a key driver of psoriasis, and its 
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neutralization in patients, or receptor blockade improves the 
skin condition (1).
The cytokine IL-9 is involved in chronic inflammation and has 
recently been associated with psoriasis (22, 23). We have demon-
strated how S. pyogenes preferentially induces IL-9 production 
during the coculture of autologous CLA+ T cells and epidermal 
cells in psoriasis but not in healthy controls. IL-9 is produced 
in the same culture conditions in which IL-17A and IL-17F 
are detected in a time-dependent manner. IL-9 production is 
dependent on MHC class I and class II presentation, and it pref-
erentially prolongs CLA+ T cell survival. Higher amounts of IL-9 
were detected in psoriasis patients than in healthy controls, but 
no differences were observed between GP and CPP patients (24). 
IL-9 has been associated with increased IL-17A production in an 
animal model of psoriasis (23). Since S. pyogenes induces both 
IL-9 and IL-17A, we examined the interaction between these two 
cytokines in CLA+ T cells. To this end, we blocked IL-9 function 
using a neutralizing. A 50% reduction in IL-17A production, but 
not IFN-γ, was found when was IL-9 was neutralized in CLA+ 
cells activated by S. pyogenes.
Our studies have shown that, in CPP patients without clinical 
evidence of S. pyogenes infection, only CLA+ T cells respond to 
this microbe in comparison to healthy controls. This observation 
indicates that psoriasis patients present an adaptive immune 
response to S. pyogenes through IL-17A, IL-17F, IL-9, and IFN-γ 
production (20, 21, 24) and suggests that S. pyogenes modulates 
the response of the CLA+ T cells that maintain psoriatic lesions, 
i.e., pyogenes infection has been describe to participate in CPP 
infection, since higher levels of IgG against S. pyogenes proteins 
are detected in psoriasis patients in comparison to healthy con-
trols (25). Some studies have reported the presence of the genera 
Streptococcus in normal and psoriatic skin (26) and the isolation 
of S. pyogenes in the skin of GP patients (4), probably leading to 
cutaneous immunization and a CLA+ T cell-restricted response 
in psoriasis.
CLA+ T CeLL ReSPOnSe TO C. albicans 
in PSORiASiS
The cutaneous adaptive immune response to C. albicans infection 
is mediated by a Th17 profile since Th17  cells are essential for 
anti-fungal barrier immunity (27). Patients with Th17 deficien-
cies have an increased susceptibility to candidiasis (28), and 
CD45RA+ human T cells may lead to an increase in the number of 
IL-17 and IFN-γ-producing cells (29). Cutaneous candidal infec-
tions have been reported in association with psoriasis exacerba-
tion (30); however, the mechanisms by which C. albicans induces 
psoriasis are poorly understood (2). In psoriasis, C. albicans-
derived superantigens may induce an expansion of lymphocytes 
expressing the T-cell receptor variable region beta 5.1 (31). Like 
in the case of S. pyogenes, CLA+ T cells, together with autologous 
epidermal cells, preferentially respond to C. albicans extract by 
inducing IL-9, IL-17A, and IFN-γ production in psoriasis. This 
response appears to be restricted to CLA+CD4+ memory T cells 
since CD4-depleted CLA+ memory T cells do not respond to this 
microorganism in a coculture model with psoriasis cells (24). 
These results are in line with the expected immune response to 
C. albicans in the skin. However, the observed preferential response 
of CLA+ T cells in psoriasis suggests an adaptive immune response 
to C. albicans, underlying its importance as a relevant antigen 
likely to be involved in triggering the disease.
inFLUenCe OF S. pyogenes AnD  
C. albicans On iL-17 ADAPTive iMMUne 
ReSPOnSe in PSORiASiS
The precise mechanisms by which environmental factors trigger 
psoriasis are not well understood (1). Biological therapies have 
revealed the clinical relevance of the IL-23/IL-17 axis in this skin 
disease. Thus, environmental factors that contribute to fueling the 
IL-23/IL-17 response may induce the condition. The observation 
that CLA+ T  cells in psoriasis patients respond to skin S. pyo-
genes and C. albicans extracts indicates a relationship between 
memory T cells and environmental microbes. Such preferential 
sensitization to these microorganisms in psoriasis can be either 
at the tonsillar level in psoriasis through the abnormal generation 
of CLA+ T cells or at the skin level, since the presence of both 
S. pyogenes and C. albicans in psoriatic lesions (13). The CLA+ 
T cell response to these microbes is based on IL-17A, IL-17F, IL-9, 
and IFN-γ production. This response indicates that these skin-
homing cells will migrate to psoriatic lesions and thus that they 
may be involved in the local inflammatory response. IL-17A and 
IL-17F are clinically validated mediators of psoriasis. S. pyogenes-
driven IL-9 production through CLA+ T cells supports IL-17A 
production in human lymphocytes, since in vitro neutralization 
of IL-9 reduces IL-17A production by 50% (24).
A current model of IL-17 production in psoriasis considers 
that some autoantigens, such as LL-37 and ADAMTS-like protein 
5, would activate T17 cells (32), initiating the immune circuit of 
the psoriasis pathogenetic mechanism in the disease. Also, IL-23 
production by inflammatory dendritic cells favors the generation 
and maintenance of the T17 phenotype in psoriasis. Interestingly, 
regarding the possible interplay between C. albicans and S. pyo-
genes and the IL-23/Th17 axis, it has been recently shown that 
C. albicans stimulates dendritic cells to release IL-23 (33). There 
is a complex interplay between these two microbes and CLA+ 
T cells in psoriasis; however, the influence of microbes in psoriasis 
may be more complex that originally believed since microbiota 
studies demonstrate the presence of a range of microorganisms 
in psoriatic lesions (34). The functional relevance of these micro-
organisms for the disease has not been determined (35).
In summary, the observations made to date suggest that 
circulating CLA+ T cells in psoriasis patients produce increased 
amounts of IL-17A, IL-17F, and IL-9, in comparison to healthy 
controls, when activated by S. pyogenes (Figure 1). Interestingly, 
the response to C. albicans is restricted mainly to CLA+ T cells 
in cocultures with autologous epidermal cells in psoriasis with 
a similar cytokine profile. Psoriatic lesions produce several 
chemokines to attract skin-seeking CLA+ T cells (21) with IL-17 
capacity to the skin with potential to induce IL-17-dependent 
autoantigens and promote and maintain lesion activity. The 
study of the cutaneous immune response of CLA+ T cells allows 
us to gain insight into how environmental factors, such microbes, 
shape psoriasis inflammation.
FiGURe 1 | Candida albicans and Streptococcus pyogenes induce IL-17 response in circulating CLA+ T cells in psoriasis, thereby indicating an established adaptive 
immune response to these microorganisms in this disease. Upon migration to cutaneous lesions, these cells react with those microbes and locally trigger IL-17 and 
IL-9 production, which will contribute to inducing psoriasis autoantigens.
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